Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) was upgraded by stock analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating in a note issued to investors on Monday.

Several other equities research analysts have also recently issued reports on CATB. Zacks Investment Research cut shares of Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 16th. Oppenheimer Holdings, Inc. raised their price objective on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research report on Thursday, October 5th. CIBC restated an “outperform” rating and set a $7.00 price objective (up from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Cowen and Company restated a “market perform” rating and set a $2.00 price objective on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. Finally, HC Wainwright raised their price objective on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $4.89.

Shares of Catabasis Pharmaceuticals (NASDAQ CATB) opened at $1.62 on Monday. Catabasis Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The business had revenue of $0.25 million during the quarter. research analysts forecast that Catabasis Pharmaceuticals will post -1.42 earnings per share for the current fiscal year.

WARNING: “Catabasis Pharmaceuticals, Inc. (CATB) Lifted to “Buy” at Citigroup Inc.” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/catabasis-pharmaceuticals-inc-catb-lifted-to-buy-at-citigroup-inc/1715376.html.

A number of institutional investors have recently added to or reduced their stakes in CATB. Wedbush Securities Inc. increased its position in Catabasis Pharmaceuticals by 2,368.6% during the third quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock worth $534,000 after purchasing an additional 241,602 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Catabasis Pharmaceuticals during the second quarter valued at about $271,000. Renaissance Technologies LLC acquired a new stake in shares of Catabasis Pharmaceuticals during the first quarter valued at about $106,000. Finally, Oppenheimer & Co. Inc. increased its position in shares of Catabasis Pharmaceuticals by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 49,000 shares during the last quarter. Hedge funds and other institutional investors own 32.23% of the company’s stock.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.